Shatavari

Depression and anxiety are among the most common mental health disorders, affecting millions of people worldwide and significantly impacting quality of life. Conventional pharmacological treatments, including antidepressants and anxiolytics, often come with side effects, dependency risks, and limited efficacy, prompting the need for alternative therapeutic options. Shatavari ( Asparagus racemosus ), a widely used herb in Ayurveda, has gained attention for its potential neuroprotective, adaptogenic, and mood-enhancing properties. Research suggests that its bioactive constituents, including steroidal saponins, flavonoids, and alkaloids, contribute to its antidepressant and anxiolytic effects by modulating neurotransmitters such as serotonin, dopamine, and GABA; reducing oxidative stress and inflammation; and promoting neurogenesis. Preclinical studies have demonstrated its efficacy in animal models of depression and anxiety, while emerging clinical evidence supports its role as a natural alternative or adjunct to conventional treatments. Additionally, advancements in formulation science, including nanoformulations and bioenhanced delivery systems, aim to improve its bioavailability and therapeutic effectiveness. While Shatavari presents a promising natural intervention for mental health disorders, further large-scale clinical trials and regulatory standardization are required to establish its safety, efficacy, and integration into mainstream psychiatric care. This chapter explores the phytochemistry, pharmacological mechanisms, preclinical and clinical evidence, formulation strategies, safety considerations, and future prospects of Shatavari as a novel therapeutic for depression and anxiety.